- Chris Boshoff to lead all Research and Development functions
including Oncology
- Oncology Unit end-to-end structure to remain intact, reporting
to Boshoff
- Roger Dansey to become Interim Chief Oncology Officer and
Johanna Bendell to join Pfizer as Oncology Chief Development
Officer
Pfizer Inc. (NYSE: PFE) today announced that after a
comprehensive internal and external selection process, the company
is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer
and President, Research & Development effective January 1,
2025. Dr. Boshoff, who most recently served as Chief Oncology
Officer and Executive Vice President, will succeed Dr. Mikael
Dolsten whose departure from Pfizer was announced earlier this
year. In his new role, Dr. Boshoff will remain a member of Pfizer’s
Executive Leadership Team reporting to Chairman and Chief Executive
Officer, Dr. Albert Bourla, and he will oversee all functions of
Research & Development across all therapeutic areas.
Pfizer’s Oncology R&D organization will maintain its fully
integrated structure with Roger Dansey, M.D. serving as Interim
Chief Oncology Officer, reporting to Dr. Boshoff effective January
1, 2025. Dr. Dansey will assist Dr. Boshoff in selecting a
permanent Chief Oncology Officer, after which time he will retire
from Pfizer. He will also facilitate a smooth transition of his
current responsibilities to his successor, Johanna Bendell, M.D.
who will be joining Pfizer from Roche in 2025 as Chief Development
Officer, Oncology.
“Dr. Boshoff is the ideal leader to propel Pfizer’s R&D
engine forward and transform it into a world-leading organization
with a more focused strategy, driving the delivery of additional
impactful breakthrough medicines with blockbuster potential,” said
Dr. Bourla, Chairman and Chief Executive Officer. “Chris has a
compelling vision for the future of R&D at Pfizer and deep
knowledge of our entire pipeline and R&D organization that
positions him well to succeed. He has an impressive record of
building strong teams and delivering numerous breakthrough
medicines. Under Chris’ leadership, Oncology has become one of
Pfizer’s most productive divisions and his continued supervision
will ensure that we achieve our goal of being a global leader in
oncology and other core therapeutic areas.”
During Dr. Boshoff’s more than 11 years at Pfizer, he has
delivered an impressive 24 approved innovative medicines and
biosimilars in more than 30 indications. Prior to becoming Chief
Oncology Officer, Chris served as Chief Development Officer for
Oncology and Rare Disease, and he also previously served as Head of
Development Japan across all therapeutic areas. Before assuming
leadership roles in the biopharmaceutical industry, Dr. Boshoff
served as founding Director of the University College London (UCL)
Cancer Institute. He earned his medical degree from University of
Pretoria in South Africa, a doctorate Ph.D. from the Institute of
Cancer Research in London and trained as a medical oncologist at
the Royal Marsden and Royal Free Hospitals in London. He is an
elected Fellow of the U.K. Academy of Medical Sciences.
“I am honored to be succeeding Mikael and to be taking on
leadership of a combined R&D organization that includes
world-class talent and capabilities, industry leading success rates
and cycle times, and a promising pipeline of innovative medicines
and vaccines candidates poised to have a tremendous impact for
patients globally,” said Dr. Chris Boshoff. “I look forward to
working even more closely with Albert, our executive leadership
team, and our entire R&D organization to take Pfizer’s pipeline
and productivity to the next level. I am confident that we can
build on our long history of successes and drive even deeper focus
on advancing the most impactful programs in areas of high unmet
medical need that will have a meaningful impact on patients
worldwide.”
After joining Pfizer through the Seagen acquisition, Dr. Roger
Dansey has served as the Chief Development Officer, Oncology. At
Seagen, he served as Chief Medical Officer since 2018 and interim
CEO in 2022, leading clinical development efforts for PADCEV,
TUKYSA, and TIVDAK, as well as securing supplemental approvals for
ADCETRIS. Previously, he led Clinical Oncology Research at Merck,
overseeing KEYTRUDA®i (pembrolizumab) registration efforts.
Dr. Johanna Bendell is currently Global Head of Oncology, Pharma
Research and Early Development at Roche. Previously, she held
significant roles at Sarah Cannon Research Institute, including
Director of Gastrointestinal Oncology Research and Chief
Development Officer. She also held positions at Duke University
Medical Center and Harvard Medical School. Johanna holds a Doctor
of Medicine degree from The University of Chicago Pritzker School
of Medicine and a Bachelor of Science in Biochemistry from the
University of Chicago. Her medical training includes a residency at
Brigham and Women's Hospital and an oncology fellowship at
Dana-Farber Cancer Institute.
About Pfizer: Breakthroughs That Change Patients’
Lives
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products, including innovative medicines and vaccines. Every day,
Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our
responsibility as one of the world's premier innovative
biopharmaceutical companies, we collaborate with health care
providers, governments and local communities to support and expand
access to reliable, affordable health care around the world. For
175 years, we have worked to make a difference for all who rely on
us. We routinely post information that may be important to
investors on our website at www.Pfizer.com. In addition, to learn
more, please visit us on www.Pfizer.com and follow us on X at
@Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook
at Facebook.com/Pfizer.
Disclosure Notice: The information contained in this
release is as of November 20, 2024. The Company assumes no
obligation to update forward-looking statements contained in this
release as the result of new information or future events or
developments.
This release contains forward-looking statements about, among
other things, Pfizer’s research and development organization and
strategy, goals, prospects, products and product pipeline,
including their potential benefits and breakthrough and blockbuster
potential, that involves substantial risks and uncertainties that
could cause actual results to differ materially from those
expressed or implied by such statements. Risks and uncertainties
include, among other things, the uncertainties inherent in research
and development, including the ability to meet anticipated clinical
endpoints, commencement and/or completion dates for our clinical
trials, regulatory submission dates, regulatory approval dates
and/or launch dates, as well as the possibility of unfavorable new
clinical data and further analyses of existing clinical data; risks
associated with interim and preliminary data; the risk that
clinical trial data are subject to differing interpretations and
assessments by regulatory authorities; whether regulatory
authorities will be satisfied with the design of and results from
our clinical studies; whether and when any drug applications,
biologics license applications and/or emergency use authorization
applications may be filed in any jurisdictions for any potential
indication for Pfizer’s product candidates; whether and when any
such applications that may be pending or filed for any of Pfizer’s
product candidates may be approved by regulatory authorities, which
will depend on myriad factors, including making a determination as
to whether the product's benefits outweigh its known risks and
determination of the product's efficacy and, if approved, whether
any such product candidates will be commercially successful;
decisions by regulatory authorities impacting labeling,
manufacturing processes, safety and/or other matters that could
affect the availability or commercial potential of Pfizer’s product
candidates, including development of products or therapies by other
companies; manufacturing capabilities or capacity; uncertainties
regarding the ability to obtain recommendations from vaccine
technical committees and other public health authorities and
uncertainties regarding the commercial impact of any such
recommendations; the uncertainties inherent in business and
financial planning, including, without limitation, risks related to
Pfizer’s business and prospects, adverse developments in Pfizer’s
markets, or adverse developments in the U.S. or global capital
markets, credit markets, regulatory environment or economies
generally; the impact of COVID-19 on our business, operations and
financial results; and competitive developments.
A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2023 and in its subsequent reports on Form 10-Q,
including in the sections thereof captioned “Risk Factors” and
“Forward-Looking Information and Factors That May Affect Future
Results”, as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
and available at www.sec.gov and www.pfizer.com.
i KEYTRUDA is a registered trademark of Merck Sharp & Dohme
Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Category: Corporate, Leadership, Research
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241120053273/en/
Media: PfizerMediaRelations@Pfizer.com +1 (212) 733-1226
Investor: IR@Pfizer.com +1 (212) 733-4848
Pfizer (NYSE:PFE)
過去 株価チャート
から 11 2024 まで 12 2024
Pfizer (NYSE:PFE)
過去 株価チャート
から 12 2023 まで 12 2024
